<DOC>
	<DOCNO>NCT00294086</DOCNO>
	<brief_summary>This study evaluate tolerability safety valsartan patient stable , chronic heart failure ( NYHA Class ll-lll ) . The 12-week double blind study 2-week ( maximum ) screening , 10-week active treatment phase . In treatment arm ( QD BID ) , patient up-titrated maximum valsartan total daily dose 320 mg . Patients remain prior CHF standard care therapy throughout study period , up-titration valsartan base patient tolerability .</brief_summary>
	<brief_title>A Study Valsartan Administered Once Daily Versus Twice Daily , Patients With Stable , Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion Criteria Males female age 18 year old Diagnosis chronic heart failure ( CHF ) , NYHA Class lllll begin least 3 month prior Visit 1 Patients must remain prior standard care CHF therapy Exclusion Criteria Diagnosis severe hypertension ( SBP &gt; 180 DBP &gt; 110 mm Hg ) Right heart failure due pulmonary disease Presence rapidly deteriorate heart failure MI cardiac surgery , include PTCA within 3 month Visit 1 Unstable angina coronary artery disease likely require CABG PTCA Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>valsartan ,</keyword>
	<keyword>chronic heart failure ,</keyword>
</DOC>